Charterhouse Capital-backed SERB and Stark International Lux completed the acquisition of Boston Scientific's BTG Specialty Pharmaceuticals business for $800m.

Charterhouse Capital-backed SERB, a European specialty pharmaceutical group, and Stark International Lux, a holding company, completed the acquisition of the BTG Specialty Pharmaceuticals business from Boston Scientific, a provider of medical solutions, for $800m. "BTG Specialty Pharmaceuticals and SERB are an excellent strategic fit, with complementary portfolios, geographies, and capabilities. The combined company is now a truly global specialty pharmaceutical business with a diversified portfolio of critical care medicines and a growing presence in rare diseases. This creates a platform for growth and broadens the scope for further strategic acquisitions," Jeremie Urbain, SERB CEO.